Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.46 EUR | +3.24% |
|
-4.00% | -17.71% |
07-01 | Akeso, Inc. Announces Change of Directors | CI |
06-04 | Akeso Expands Territory of License Agreement for Lung Cancer Drug | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-17.71% | 4.12B | - | ||
+15.58% | 122B | B+ | ||
+16.60% | 113B | B+ | ||
+17.55% | 26.22B | B | ||
-24.33% | 19.01B | B+ | ||
-19.14% | 15.71B | A- | ||
-17.95% | 15.22B | B | ||
-46.81% | 14.72B | A- | ||
+58.78% | 14.58B | C+ | ||
+4.91% | 13.84B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 9926 Stock
- 4RY Stock
- Ratings Akeso, Inc.